Okay. It's just about 5:00 P.M., so I think we can get started. Thanks very much for joining this session. My name's Steve Barker. I cover Japanese healthcare for Jefferies in Japan, and it's my pleasure to be hosting this session with Takeda Pharmaceutical Company. We have the CEO, Julie Kim. We have Andy Plump, Head of R&D, and we also have Milano Furuta, CFO. Everybody, thanks very much for joining us. I'd like to jump straight in with a question for you, Julie.
Sure.
I think a lot of companies would be excited to even have one blockbuster, something as interesting as ORZEYFUL for your narcolepsy type one program, but you actually have three very exciting blockbusters coming out.
Yes.
You also have MIMRYLO for polycythemia vera, and then very soon, you're very likely to get approval for zasocitinib for psoriasis. How are you preparing to give these three opportunities the attention they deserve?
Yeah. Look, we've already launched two of them, and so I would say this. From a total company perspective, we're making sure that we have the right level of resources dedicated to each of these launch assets, and happy to say that both for MIMRYLO and ORZEYFUL that have launched, they are doing really well. Very pleased about their performance to date, and as you said, we're waiting for zasocitinib. We do have priority review with the FDA, and we expect to have an answer in March.
Okay, that's great. Andy, I have a question for you around zasocitinib. It's been encouraging to see that there clearly is demand for oral treatments for psoriasis. We've seen that in the market. Do you think dermatologists are ready to embrace alternatives to the injectables?
Well, maybe I'll start, Julie, and I'll hand it over to you and just talk a little bit about the profile of zasocitinib in psoriasis. When we brought this compound in over four years ago, we were excited about the data that we had seen, and every data set that we've revealed since then has just made us even more excited. We actually just had head-to-head data with deucravacitinib, so it's not really kind of a poised competition for us, but it's a benchmark, and it suggests the level of efficacy that we have. It's very unusual to go head-to-head against another member in the same class. We did that on our primary endpoint, which was 100% skin clearance. We had a 2.5 times greater effect.
We saw, just by point estimate, the most significant effects on this endpoint, PASI 100, in any psoriasis trial at week 16, which is about 36%.
Yeah, when you look at the oral segment today, and if we just focus on the U.S. market for a moment, the oral segment today represents roughly 10% of the overall, and we do believe that there's significant room for that segment to grow. J&J, as you know, has launched last year into this space with an effective oral. We do believe that there's room for more than one oral, and we like zasocitinib's profile. So, in addition to the great data that Andy mentioned, we don't have a food restriction for zasocitinib. zasocitinib works very well across all patient types within psoriasis, and we have fast onset of activity, of efficacy, strong durability. There's nothing that we are worried about when it comes to zasocitinib, so we're looking forward to the eventual approval and another launch.
Very effective data, as you mentioned, Andy. Where do you see the opportunity with the patients? Is it patients who do not want to have injections for some reason, or where is the opportunity?
Yeah. When you look at the progression of patients onto therapy. First, going onto an injectable is quite a scary thing, but if you have really severe disease, you probably will. Most would like to try an oral first, but the existing oral previously was not that effective across patient types. Now they have had an effective oral for one year, and we have seen the pickup of that. So again, zasocitinib, as another really effective oral agent, the profile that it has, we think it will do well.
Right. Milano, I have a question for you. Three major launches. It is a nice problem to have, but it does require substantial investment upfront. I know you have a cost-saving program underway. Could you tell us something about that? How are you funding the investment that these launches require?
Yeah. This year, we are already increasing commercial investments. We are planning to invest almost like JPY 100 billion. It is almost the same amount, JPY 100 billion for the commercial investments. Perhaps it is highly likely we increase a little bit more for next year, because it is going to be the first full year launching those three products. In the meantime, we are running the transformation program, the cost savings program, with combining more like strategic organizational change program. We are making Basically, the big change in organizationally, we are delayering some management layers, we are centralizing some corporate functions, we are leveraging some global capability centers. So the making more efficient organization, process standardization, and then getting the savings to fund all those commercial launches. So that is how we are managing the incremental cost investments by the cost savings program.
Right. JPY 100 billion investment this year, going up a little bit next year.
Yeah.
You have the ongoing savings program. What I am hearing is that you should be able to see some profit flowing to the bottom line in the relatively near future.
Yeah. I think I would be a bit more cautious on that side because, again, we are now launching the three new products, and then again next year will be a first full year.
Right.
Okay, first full year. So, annualization of the commercial spends.
Right.
Of course, and we do have the savings as well. Savings will be fully annualized
Yeah
the next year.
Right.
But any launches, you do not see the profit accretive from year one.
Right.
So that is perhaps still you do not see the right away
Yeah
kind of profit accretive, but that is how we are managing those investments.
Right
and all the savings. Don't forget that also we are developing the next wave
Yeah
of the new products. Not only the three products launches, but we have a bunch of the phase III programs. That is where we are also increasing investment. That is how you should look at the P&L.
Right. That actually brings me to the next question, the stages of growth. You have these three big launches happening right now, but then you have a very exciting pipeline coming up before. You have TAK-360 in sleep disorders, you have mezagitamab in autoimmune diseases, you have an oncology program. How should we be looking? You've talked about the stages of growth. Could you talk specifically about how that relates to these drugs and these programs?
Yeah. So, a couple of comments, Steve. When you look at our overall portfolio, we're not shifting our therapeutic areas, but what we are trying to do is build more depth behind these franchises. That's not something that we've necessarily had a lot of depth in the past, and that is what we are focused on. When you look at, for example, with ENTYVIO, now we have ENTYVIO, we have TAK-279, we have zasocitinib being developed in IBD, and we will continue to build behind that as well. That's one comment. Then separately, in terms of the phases of growth that we've laid out for the company, we've talked about Horizon One, where we are transforming the organization, a bit of what Milano was just mentioning, and we have these three launches that will be the start of our new cohort of assets.
The rest of our portfolio that is in market is relatively mature. Of course, we still have to ensure that that portfolio performs, but it's not going to be a strong driver of future growth. That's why we said in this Horizon One period, it'll be low growth. We're going to try to do our best to protect our core operating profit margins. As you heard from Milano, we are going to be reinvesting our savings behind the launches and the pipeline development. All of this will then set us up for Horizon Two, where these first launches will reach scale, and then we will start launching the second wave of products. That is really what will start creating the longer-term sustainable growth for us.
Right. Well, I would like to drill down a little bit into some of the franchises and the broader orexin opportunity. You are the leader with orexins. You already have ORZEYFUL on the market. But you have other assets coming behind, TAK-360. Andy, perhaps you could talk to the science. Are you very excited about orexin-2 agonists?
Very. So you have asked me to talk about the science, now I am really excited.
Yeah.
Maybe I'll start out, Steve, just by way of understanding the, in a sense, the pyramid of the diseases that we could potentially treat with orexin agonists, and start out by defining the underlying biology. Narcolepsy type 1 is different from every other condition where you could potentially use an orexin agonist in that it's a deficiency of orexin.
Every other disease that we're talking about, whether it's type 2 narcolepsy, whether it's idiopathic hypersomnia, obstructive sleep apnea, whether it's any condition that's characterized by fatigue or attention deficit, or you fill in the blank, all of those conditions are characterized by normal orexin levels. So the dose in type 1 narcolepsy is much lower. The consistency of effect, I think, is going to be something that will be somewhat unique to type 1 narcolepsy. Of course, we'll see this as the rest of this plays out. For us, we have ORZEYFUL, which is laser-focused on type 1 narcolepsy, and then we have a suite of other molecules. Two are in the clinic right now, TAK-360 and TAK-495.
A third will be coming into the clinic. These are all orexin-2 receptor agonists with different properties that we think will play to some of these indications in different ways. Then behind that, we have a very substantive effort in the laboratory to come up with a next-generation pharmacology, let's say. An example would be interest in the orexin-1 receptor. So dual pharmacology with the orexin-1 receptor. The potential is massive. We have obviously the most opportunity in front of us in narcolepsy type 1, but the potential here is quite significant.
That's interesting, Andy. It sounds like you are developing these different compounds targeted for some of these different indications that you mentioned. So there is differences in the way that these drugs are working?
There are. People always think about potency. Potency ends up being not the least important factor, but a pretty unimportant factor in many respects, because the orexin-2 receptor agonists all are generally sufficiently potent. So you have to look at PK, you have to look at blood-brain barrier penetration, off-rate on the receptor. There are just a host of factors that ultimately will play into these molecules. For some indications, we have a fair understanding of what those relationships are to the diseases. In other places, there's a lot of learning. So our intent is to have a range of different molecules that have different features. There's also going to be just a commercial positioning, because you're going to be talking about low volume, high price point, like narcolepsy type 1 or narcolepsy type 2, and then higher volume, lower price point.
If we were to go into, for example, excessive daytime sleepiness across indications or attention deficit or cognition, which is something that these molecules could play in many, many indications, that you're talking obviously about a very different commercial model.
Right. You've mentioned sleep apnea, attention deficit disorder. There are other companies which are looking at these drugs in depression. It really sounds like there's a very big potential.
Yeah. This is a plug for our Capital Markets Day on December 11th. You should all come to Tokyo or get up early and watch us, because we're going to be spending the whole day talking about the evolving strategy under Julie, and a large focus will be on these franchises, including orexin.
Right. Andy, I have another question for you. zasocitinib, hoping to get approval for first indication soon, but you're also developing it for inflammatory bowel disease. You had some interesting data recently. Could you talk to that, please?
Sure. Psoriasis launch coming in March, psoriatic arthritis data coming next year, and then phase II data for UC and Crohn's disease we'll disclose end of the fiscal year.
Right.
We shared some top-level comments around the UC study, which read out six weeks ago. We actually have a very robust effect.
The effect, and we talked about this, we haven't provided any specific data, but it's directionally on par with what's been seen by other agents, oral agents in ulcerative colitis, other agents in development. You can kind of get a sense for what that effect size is. The complexity is that we saw that at the middle dose, but not the high dose.
Right.
We lost It's a kind of a bell-shaped dose response curve. Two comments about that. One is that that creates a complexity. That's obvious. The second is it's not uncommon with diseases, especially in IBD, but broadly as anti-inflammatory mechanisms, and probably reflects homeostasis within the immune system. As you start to go past a certain threshold, the immune system often reverses on itself as a protective mechanism. We have some reasons that we think molecularly can explain this. But the explanation will come when we see the Crohn's data.
Right.
That will be at the end of the year. We're moving ahead
Right
as if we're going to start phase III, so we're doing all of the work that would be necessary. Then once we get the Crohn's data, we'll finalize our go/no-go decision as well as the specifics like dose.
Right. To be clear, you're not disappointed with the data?
No, I'd say the opposite. I'd say when we started the program, we were more enthusiastic mechanistically about a benefit in Crohn's than UC.
Right.
When we saw these data, it creates a headache that you have this kind of dose response curve.
Right.
But in terms of what we're seeing at that middle dose, it's very encouraging.
I think it does make the upcoming Crohn's data particularly important. How will that add to your understanding of this class, this drug, in this indication?
Well, if it works, I think we've got a great addition to the armamentarium of oral agents for IBD.
Right. What is the base case? You will develop the drug for both UC and Crohn's?
That is right.
Okay.
Yeah.
Terrific. Okay. Milano, back to you. Capital allocation, shareholder returns is always a very important topic. You have obviously an R&D pipeline here to fund. How do you decide on the best use of capital, investing in clinical programs or licensing assets? How do you think about that?
Yeah. Our usage of the capital is, the free cash flow-wise, the investment of growth, deleverage, and dividends.
Right.
Starting from dividend, we have a progressive dividend policy, which means basically either maintain or increase dividends. We want to make some sort of a certain predictability on the sustained, but long-term sustainable growth on the dividends. That's kind of one portion. If you look at it from free cash flow perspective, almost like now 40% of the free cash flow is going to the dividends. The other element is in a deleverage. We still have relatively high the level of the debt in this industry, like average perspective. Our net debt adjusted EBITDA ratio-wise, we are now 2.5.
Right.
We are bringing down from a much higher level so that it gives us more flexibility in terms of some firepower. But still, we want to manage this debt level a little bit lower. So that before the ENTYVIO biosimilar entry in the U.S., we want to bring it down to two. That's another element of how we are allocating free cash flow. Then the third one is a really important one, is the investment for the growth.
We are very busy to develop those in the pipeline. We have pretty good assets on hands. With all of this, we are quite confident to overcome this ENTYVIO LOE in the future. But still, we are also open to looking at any opportunities, good complementary assets that can give us the kind of more depth, what Julie mentioned, the depth in the therapeutic area of choice. Then we are happy to make some bolt-on-
additional licensing, acquisition.
Right.
Yeah.
Net debt to EBITDA right now at about 2.5 times, but you would like to get it closer to two.
Yeah.
You started off at five times, so you have come a long way.
Yeah.
I think arguably, you probably do have more flexibility. If you were to consider business development opportunities, I think this is a question for you, Julie. Where do you see the biggest opportunities? Clearly, you have leading positions in gastroenterology, neuroscience, oncology, and BD decisions, it is very important. It really gives you the option of taking the company in a certain direction. How do you weigh up the opportunities ahead of you?
Yeah. Look, we like the areas that we are in today. This is not about doing an acquisition to enter into a new therapeutic area.
Right.
But as I mentioned, we do want to build more depth
Right
in these franchises.
Right.
What we are looking for are assets that fit nicely into the spaces that we are trying to develop the deeper pipeline.
Right.
Our late stage is quite active at the moment across all three areas, so we would be most looking in the earlier
stages to fill out that part of the pipeline.
Right.
Now, of course, if there is something that is really attractive late stage
Right
we will still look, but the focus would be on the earlier stage.
Right. So focus on the therapeutic areas that you are in right now and probably earliest stage rather than commercial.
Yeah.
Okay. So, well, on that topic of innovation, China has suddenly become a huge source of innovation, and you have made use of that. Perhaps you could talk a little bit more about how do you see China developing as a source of innovation for Takeda?
Yeah. Look, I think China has become a source of innovation for the whole industry at this point. I mean, this audience is very well aware that China has evolved from a fast follow me too approach to actually having very exciting, innovative assets. For Takeda, this is where we've done a number of deals to bring in assets into our pipeline, and we continue to look at China as an opportunity to identify new assets, but also in terms of how we leverage China in our overall clinical development plan.
Of course, being conscious of the geopolitical tensions that exist, but it is a place where you have to be.
Right. Andy, I understand you're heading for retirement next year. Is-
You saw the memo.
Well, congratulations. I would just love if you could share perhaps your perspective on the time that you've spent at Takeda and beyond. You've had a long career. How has the process of R&D changed over the years?
Yeah, it's amazing. Thank you very much, by the way, and thanks for the question. It's been amazing and a privilege, especially the time at Takeda. It's been great also having a chance to transition with Julie and help with building this next stage for Takeda. I wish I knew what I knew today when I started this job. I bet you would hear that from every R&D head. That would be one thing that I would wish for. In terms of looking forward, I think, and you and I were talking about this just in the hallway outside, the pace of change in our industry is unlike anything we've ever seen.
I think the biggest challenge, the biggest opportunity is that there's so much that we can do so fast. Science is just taking off, and our ability to translate that science is taking off operationally, our ability to unravel disease biology, make molecules. The application of AI is fundamentally shifting everything in our business. It is not hype, it is reality. I think the biggest challenge that we face is that because things are going so quickly, our cycle times make programs often irrelevant.
Right.
How do we navigate speed? I think that is going to be the biggest challenge and opportunity in our future.
Right. Well, I guess that has implications for your BD strategy as well. You do not have time to start from scratch.
Yeah. I mean, you have always had to do BD, because success is stochastic in our industry. I think there is another added element of, in some areas, you are going to have to wait. I think you are going to be reluctant to start a program because you just do not know what the pricing landscape will look like, what the competitive landscape will look like. In other areas, I think, in areas where you have that leadership edge and that deep vertical expertise, I think that is where you want to make investments.
Right. Okay. We're running out of time, but Julie, I'd love if you could just share with us what you've seen since you became CEO. I mean, we've covered a lot of space today. You've got these three big launches. You've got a new pipeline coming through. What opportunities most excite you about Takeda, and where do you think the gap between investors' understanding of Takeda and how you feel about the company?
Yeah. Look, I think we have tremendous potential in our pipeline, and these three assets that we've talked about today are just the beginning of that. I think where the greatest gap is, the question that we get the most is, can Takeda continue to grow beyond ENTYVIO, the LOE that is coming in a number of years? This is where we will spend a big part of our Capital Markets Day explaining how we view our ability to continue that growth and have very sustainable growth over the coming horizons.
Fantastic. Thank you very much.
Thank you.
Thank you.